Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

88.59 -0.40 (-0.45%)
Streaming Delayed Price Updated: 1:47 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
73 74 Next >
News headline image
Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership ↗
 
Via Benzinga
Topics Initial Public Offering
News headline image
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
News headline image
Danaher Corporation Poised for Growth as Q3 2025 Earnings Spark Optimism
Washington D.C., October 22, 2025 – Danaher Corporation (NYSE: DHR) is currently experiencing a wave of positive sentiment, with its stock price widely expected to rise following a robust third-quarter... 
Via MarketMinute
AstraZeneca’s Enhertu Achieves Record Response Rate In Phase 3 Trial For Early Breast Cancer ↗
Via Stocktwits
AstraZeneca Reportedly Nears Drug Pricing Deal With President Trump ↗
Via Stocktwits
News headline image
Peering Into AstraZeneca PLC's Recent Short Interest ↗
 
Via Benzinga
News headline image
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
From AstraZeneca
Via Business Wire
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash ↗
AstraZeneca's Enhertu could help some breast cancer patients avoid surgery, according to a study unveiled Saturday at ESMO. 
Via Investor's Business Daily
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
From AstraZeneca
Via Business Wire
News headline image
Invo Fertility Stock Is Plunging After White House Announcement ↗
INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible. 
Via Benzinga
News headline image
IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
From AstraZeneca
Via Business Wire
News headline image
IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
From AstraZeneca
Via Business Wire
News headline image
UK Finance Minister Seeks More Pharma Investment In Exchange For Higher Drug Prices: Report ↗
UK finance minister Rachel Reeves told reporters that the country needs to be an attractive place for pharma, including in terms of pricing. 
Via Benzinga
News headline image
Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients ↗
Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer with a consistent safety profile. 
Via Benzinga
News headline image
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades ↗
These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial. 
Via The Motley Fool
News headline image
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs ↗
Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 diabetes. 
Via Benzinga
News headline image
AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug ↗
The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma. 
Via Stocktwits
News headline image
AstraZeneca unveils expanded manufacturing facility in Texas
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca PLC (NASDAQ:AZN): A Caviar Cruise Quality Investment ↗
Discover AstraZeneca, a top-quality stock with strong growth, high ROIC, and robust cash flow. A prime candidate for long-term investors seeking durable competitive advantages. 
Via Chartmill
News headline image
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential ↗
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion. 
Via Benzinga
News headline image
Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
From AstraZeneca
Via Business Wire
News headline image
Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans ↗
Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing model. 
Via Benzinga
Topics Government
News headline image
UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments ↗
UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies. 
Via Benzinga
News headline image
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Economy Intellectual Property Retirement
News headline image
AstraZeneca Expands Virginia Investment To $4.5 Billion For Cancer, Obesity Drugs ↗
AstraZeneca will invest $4.5 billion in a Virginia facility, creating 3,600 jobs and producing advanced cancer and metabolic medicines using AI and automation. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch ↗
Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers. 
Via Benzinga
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
73 74 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.